272 related articles for article (PubMed ID: 27931793)
21. Deciphering the Evolution of Cephalosporin Resistance to Ceftolozane-Tazobactam in Pseudomonas aeruginosa.
Barnes MD; Taracila MA; Rutter JD; Bethel CR; Galdadas I; Hujer AM; Caselli E; Prati F; Dekker JP; Papp-Wallace KM; Haider S; Bonomo RA
mBio; 2018 Dec; 9(6):. PubMed ID: 30538183
[No Abstract] [Full Text] [Related]
22. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study.
Tato M; García-Castillo M; Bofarull AM; Cantón R;
Int J Antimicrob Agents; 2015 Nov; 46(5):502-10. PubMed ID: 26315199
[TBL] [Abstract][Full Text] [Related]
23. Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection model.
Vanscoy B; Mendes RE; Castanheira M; McCauley J; Bhavnani SM; Forrest A; Jones RN; Okusanya OO; Friedrich LV; Steenbergen J; Ambrose PG
Antimicrob Agents Chemother; 2013 Sep; 57(9):4134-8. PubMed ID: 23774429
[TBL] [Abstract][Full Text] [Related]
24. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).
Solomkin J; Hershberger E; Miller B; Popejoy M; Friedland I; Steenbergen J; Yoon M; Collins S; Yuan G; Barie PS; Eckmann C
Clin Infect Dis; 2015 May; 60(10):1462-71. PubMed ID: 25670823
[TBL] [Abstract][Full Text] [Related]
25. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12).
Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN
J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579
[TBL] [Abstract][Full Text] [Related]
26. Expression of CTX-M-15 limits the efficacy of ceftolozane/tazobactam against Escherichia coli in a high-inoculum murine peritonitis model.
Canovas J; Petitjean G; Chau F; Le Monnier A; Fantin B; Lefort A
Clin Microbiol Infect; 2020 Oct; 26(10):1416.e5-1416.e9. PubMed ID: 32629024
[TBL] [Abstract][Full Text] [Related]
27. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
[TBL] [Abstract][Full Text] [Related]
28. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa in the planktonic and biofilm states.
Velez Perez AL; Schmidt-Malan SM; Kohner PC; Karau MJ; Greenwood-Quaintance KE; Patel R
Diagn Microbiol Infect Dis; 2016 Jul; 85(3):356-359. PubMed ID: 27130477
[TBL] [Abstract][Full Text] [Related]
29. Ceftolozane/Tazobactam: A Review in Complicated Intra-Abdominal and Urinary Tract Infections.
Scott LJ
Drugs; 2016 Feb; 76(2):231-42. PubMed ID: 26746849
[TBL] [Abstract][Full Text] [Related]
30. Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-Resistant Pseudomonas aeruginosa.
Vickery SB; McClain D; Wargo KA
Pharmacotherapy; 2016 Oct; 36(10):e154-e159. PubMed ID: 27522066
[TBL] [Abstract][Full Text] [Related]
31. In Vitro Activity of Ceftolozane Alone and in Combination with Tazobactam against Extended-Spectrum-β-Lactamase-Harboring Enterobacteriaceae.
Melchers MJ; van Mil AC; Mouton JW
Antimicrob Agents Chemother; 2015 Aug; 59(8):4521-5. PubMed ID: 25987635
[TBL] [Abstract][Full Text] [Related]
32. Ceftolozane/Tazobactam (Zerbaxa)--a new intravenous antibiotic.
Med Lett Drugs Ther; 2015 Mar; 57(1463):31-3. PubMed ID: 25719997
[No Abstract] [Full Text] [Related]
33. Activity of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles.
Livermore DM; Mushtaq S; Meunier D; Hopkins KL; Hill R; Adkin R; Chaudhry A; Pike R; Staves P; Woodford N;
J Antimicrob Chemother; 2017 Aug; 72(8):2278-2289. PubMed ID: 28520867
[TBL] [Abstract][Full Text] [Related]
34. Ceftolozane/tazobactam for the treatment of complicated intra-abdominal infections.
Eckmann C; Solomkin J
Expert Opin Pharmacother; 2015 Feb; 16(2):271-80. PubMed ID: 25529765
[TBL] [Abstract][Full Text] [Related]
35. In vitro efficiency of the piperacillin/tazobactam combination against inhibitor-resistant TEM- and complex mutant TEM-producing clinical strains of Escherichia coli.
Robin F; Krebs M; Delmas J; Gibold L; Mirande C; Bonnet R
J Antimicrob Chemother; 2011 May; 66(5):1052-6. PubMed ID: 21393211
[TBL] [Abstract][Full Text] [Related]
36. Comparison of the risk of acquiring in vitro resistance to doripenem and tazobactam/piperacillin by CTX-M-15-producing Escherichia coli.
Horiyama T; Kanazawa S; Hara T; Izawa M; Sato T; Yamaguchi T; Tsuji M; Maki H
J Infect Chemother; 2015 May; 21(5):381-4. PubMed ID: 25662788
[TBL] [Abstract][Full Text] [Related]
37. [Post antibiotic, post beta-lactamase inhibitor and post antibiotic sub-MIC effect of ceftriaxone/tazobactam on beta-lactamase-producing Escherichia coli in vitro].
Zhang SC; Zhang LL; Chen SW; Wu HY; Liu XK
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Nov; 40(6):1071-4. PubMed ID: 20067122
[TBL] [Abstract][Full Text] [Related]
38. Exploring the effectiveness of tazobactam against ceftazidime resistant Escherichia coli: insights from the comparison between susceptibility testing and beta-lactamase inhibition.
Bethel CR; Hujer AM; Helfand MS; Bonomo RA
FEMS Microbiol Lett; 2004 May; 234(1):99-103. PubMed ID: 15109726
[TBL] [Abstract][Full Text] [Related]
39. Ceftolozane/tazobactam pharmacokinetic/pharmacodynamic-derived dose justification for phase 3 studies in patients with nosocomial pneumonia.
Xiao AJ; Miller BW; Huntington JA; Nicolau DP
J Clin Pharmacol; 2016 Jan; 56(1):56-66. PubMed ID: 26096377
[TBL] [Abstract][Full Text] [Related]
40. In vivo pharmacodynamics of piperacillin/tazobactam: implications for antimicrobial efficacy and resistance suppression with innovator and generic products.
Rodriguez CA; Agudelo M; Zuluaga AF; Vesga O
Int J Antimicrob Agents; 2017 Feb; 49(2):189-197. PubMed ID: 27988068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
